In addition, specific inhibition of SRPK1 might represent a potential anti-drug resistance therapy, and SRPK1 might also be a prognostic biomarker for oxaliplatin resistance in colon cancer. The gene discussed is SRPK1; the disease is malignant colon neoplasm.